Press "Enter" to skip to content

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc’s two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker’s growth prospects against competitor Gilead Sciences Inc.

Original source:

Also Read:   Bharat Biotech-ICMR developed Covaxin is safe, show preliminary phase I results